| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501228 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
| US8067451 | HORIZON | Methods and medicaments for administration of ibuprofen |
Jul, 2026
(2 years from now) | |
| US8067033 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
| US8309127 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
| US8449910 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
| US8318202 | HORIZON | Stable compositions of famotidine and ibuprofen |
Jul, 2026
(2 years from now) | |
Duexis is owned by Horizon.
Duexis contains Famotidine; Ibuprofen.
Duexis has a total of 6 drug patents out of which 0 drug patents have expired.
Duexis was authorised for market use on 23 April, 2011.
Duexis is available in tablet;oral dosage forms.
Duexis can be used as relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications.
The generics of Duexis are possible to be released after 18 July, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 23, 2014 |
Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient
Market Authorisation Date: 23 April, 2011
Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications
Dosage: TABLET;ORAL
DUEXIS family patents
